SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS EFFECTS OF MULTIPLE-DOSE ADMINISTRATION OF FOTAGLIPTIN BENZOATE-DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN TYPE 2 DIABETES MELLITUS

被引：0
|
作者：
Wu, Min [1 ]
Chen, Ji [2 ]
Sun, Haigang [2 ]
Zhang, Hong [1 ]
Li, Xiaojiao [1 ]
Ding, Yanhua [1 ]
Li, Cuiyun [1 ]
机构：
[1] First Hosp Jilin Univ, Changchun, Jilin, Peoples R China
[2] Shenzhen Salubris Pharmaceut Co Ltd, Shenzhen, Peoples R China
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2020年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P201
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [1] Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus
    Wu, Min
    Li, Qian-Qian
    Zhang, Hong
    Zhu, Xiao-Xue
    Li, Xiao-Jiao
    Li, Ying
    Sun, Hai-Gang
    Ding, Yan-Hua
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (06): : 660 - 668
  • [2] Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus
    Addy, Carol
    Tatosian, Daniel
    Glasgow, Xiaoli S.
    Gendrano, Isaias N., III
    Kauh, Eunkyung
    Martucci, Ashley
    Johnson-Levonas, Amy O.
    Selverian, Diana
    Matthews, Catherine Z.
    Gutierrez, Marie
    Wagner, John A.
    Stoch, S. Aubrey
    CLINICAL THERAPEUTICS, 2016, 38 (03) : 516 - 530
  • [3] Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
    Heise, T.
    Graefe-Mody, E. U.
    Huettner, S.
    Ring, A.
    Trommeshauser, D.
    Dugi, K. A.
    DIABETES OBESITY & METABOLISM, 2009, 11 (08): : 786 - 794
  • [4] Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
    Dave, Darshan J.
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2011, 2 (04) : 230 - 235
  • [5] Linagliptin: The Newest Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Aletti, Rachael
    Cheng-Lai, Angela
    CARDIOLOGY IN REVIEW, 2012, 20 (01) : 45 - 51
  • [6] Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Neumiller, Joshua J.
    Campbell, R. Keith
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) : 1515 - 1525
  • [7] Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects
    Mistry, Goutam C.
    Bergman, Arthur J.
    Luo, Wen-Lin
    Cilissen, Caroline
    Haazen, Wouter
    Davies, Michael J.
    Gottesdiener, Keith M.
    Wagner, John A.
    Herman, Gary A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02): : 159 - 164
  • [8] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Jarvis, Courtney I.
    Cabrera, Adriana
    Charron, Derek
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
  • [9] Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Johnson, Kathryn M. S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (04) : 455 - 463
  • [10] The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
    Green, Jennifer B.
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 54 - 61
12345